Fewer than 1 in 5 Americans with opioid use disorder receive medication for it, according to a 2022 study in JAMA Psychiatry — even though methadone and buprenorphine cut overdose deaths by roughly half. That gap between what works and what actually happens is where most families find themselves stuck: relieved a loved one is finally considering treatment, then confused or even suspicious when a doctor recommends a medication instead of, or alongside, therapy.
It's a reasonable place to land. Decades of messaging equated recovery with total abstinence, and the idea of treating an addiction with another controlled substance still strikes many people as swapping one dependency for another. That framing, though widely believed, doesn't hold up against the clinical evidence. Medication-assisted treatment, or MAT, is now considered the standard of care for opioid use disorder by the World Health Organization, SAMHSA, and the American Society of Addiction Medicine. Understanding how it actually works — and where its real limitations are — matters enormously if you're helping someone weigh their options among opioid addiction treatment programs.
This piece walks through what MAT is, the evidence behind it, the genuine trade-offs, and the questions worth asking before your family commits to a program. You can also compare facilities that offer MAT side-by-side in our treatment center directory, or use our assessment tool to get a clearer sense of what level of care might fit your loved one's situation.
What Medication-Assisted Treatment Actually Is
MAT combines FDA-approved medications with counseling and behavioral therapy to treat substance use disorders, most commonly opioid and alcohol use disorder. The three medications approved for opioid use disorder are methadone, buprenorphine (often known by the brand name Suboxone when combined with naloxone), and naltrexone. Each works differently.
Methadone is a full opioid agonist — it activates the same receptors as heroin or oxycodone, but slowly and steadily, without the intense high or crash. Buprenorphine is a partial agonist, meaning it activates those receptors only partially, which lowers overdose risk and eases withdrawal without producing significant euphoria in someone who's opioid-dependent. Naltrexone is an antagonist — it blocks opioid receptors entirely, so if someone relapses while taking it, the drug simply doesn't work.
For alcohol use disorder, the medications are different again: naltrexone, acamprosate, and disulfiram, each targeting cravings or the physiological reward loop in distinct ways.
None of these medications is meant to be dispensed and forgotten. The clinical model pairs them with individual or group counseling, case management, and monitoring — which is why the term is "medication-assisted treatment," not "medication-only treatment." The medication addresses the neurobiology; the counseling addresses everything else — the relationships, the trauma, the habits, the triggers.
The Evidence: Why Clinicians Recommend It
The research base for MAT, particularly for opioid use disorder, is deep and fairly consistent.
A landmark Cochrane review found that methadone maintenance treatment retains patients in treatment significantly better than non-medication approaches and reduces illicit opioid use.
NIDA-funded research has repeatedly shown that MAT reduces opioid-related overdose deaths by约 50%.
A 2018 study in the Annals of Internal Medicine found that patients treated with buprenorphine or methadone after a non-fatal overdose had substantially lower mortality over the following year compared to those who received no medication.
The CDC's data on the opioid crisis consistently shows that counties with greater access to buprenorphine prescribers see measurable reductions in overdose fatalities.
What these numbers translate to for a family is straightforward, if uncomfortable to say plainly: MAT keeps people alive long enough to do the deeper work of recovery. Someone who overdoses doesn't get a second chance at therapy. Someone stabilized on buprenorphine, with cravings blunted and withdrawal managed, has a far better shot at holding a job, repairing relationships, and staying engaged in counseling.
This is also why most reputable detox and inpatient facilities now offer or refer out for MAT rather than insisting on abstinence-only protocols — the data simply moved the field in this direction over the last fifteen years.
Where the Real Considerations Are
None of this means MAT is simple, or that every program does it well, or that it's the right fit for every person. Families deserve a clear-eyed look at the trade-offs, not just the headline statistic.
Duration and the "how long" question
There's no universal timeline. Some people stay on buprenorphine or methadone for months; others for years; some indefinitely, similarly to how a person with diabetes might stay on insulin long-term. NIDA has been explicit that longer retention in MAT correlates with better outcomes, and that tapering off too early raises relapse risk substantially. Families often want a hard end date. Clinicians frequently can't give one, and pushing for one prematurely can backfire.
Access and logistics
Methadone can only be dispensed through federally certified opioid treatment programs, which usually means daily visits, at least at first — a real burden for someone working a job or caring for children. Buprenorphine prescribing was loosened considerably by the 2023 elimination of the X-waiver requirement, so more primary care doctors and psychiatrists can now prescribe it, which has improved access but created wide variation in provider quality and follow-up support.
Diversion and misuse concerns
Buprenorphine in particular has some street value, and take-home doses carry a risk of diversion or misuse — though notably, most reported non-prescribed buprenorphine use is for self-treating withdrawal, not for getting high, according to a study published in the International Journal of Drug Policy. Programs that dispense with proper monitoring, urine screening, and pill counts largely mitigate this.
The medication is not a solo intervention
MAT without any counseling component tends to produce weaker outcomes than combined treatment. Families should ask directly whether a program's MAT offering is paired with actual therapeutic support or whether it's just prescription refills with minimal check-ins. The difference matters enormously.
Stigma, including from within recovery communities
Some 12-step or peer-support environments still view MAT skeptically, occasionally treating it as "not really sober." This attitude is increasingly out of step with clinical consensus, but it's real, and it can undermine a person's confidence in their own treatment plan if they encounter it in group settings. It's worth preparing your loved one for the possibility they'll meet this attitude, and helping them hold their ground.
What This Looks Like for Alcohol Use Disorder
MAT isn't only an opioid conversation. Naltrexone, acamprosate, and disulfiram are all approved for alcohol use disorder, and are dramatically underused — a 2019 study in JAMA Psychiatry found fewer than 10% of Americans with alcohol use disorder ever receive medication for it, despite solid evidence for reduced drinking days and improved abstinence rates when combined with counseling.
Naltrexone reduces the rewarding effects of alcohol, which can lower heavy drinking episodes even in people who haven't fully stopped. Acamprosate helps stabilize brain chemistry disrupted by chronic alcohol use, easing some of the post-acute withdrawal symptoms that drive relapse. Disulfiram creates an unpleasant physical reaction if alcohol is consumed, functioning more as a deterrent than a craving-reducer — it requires high motivation and is less commonly used today.
If your loved one's issue is alcohol rather than opioids, it's worth asking any treatment center specifically what medication options they offer, since not every facility stocks or prescribes all three.
Questions to Ask Before Choosing a Program
A few direct questions can save a family months of frustration:
Which specific medications does the program offer, and do they have in-house prescribers or do they refer out?
Is counseling mandatory alongside the medication, and how often?
What's their philosophy on tapering — do they have a fixed timeline, or is it individualized based on progress?
How do they handle relapse while on MAT? Is it treated as a crisis requiring discharge, or as part of an ongoing clinical picture?
What happens after discharge — is there a plan for continued prescribing, or does the person leave with a two-week supply and no follow-up?
That last question trips up more families than any other. A strong induction into MAT during residential treatment means little if there's no plan for who prescribes it once your loved one is back home. Comparing programs directly on this specific point — continuity of medication management post-discharge — is one of the more useful things a family can do before committing to a facility.
Supporting a Loved One on MAT
If your loved one starts MAT, your role shifts more toward patience and away from monitoring for a single moment of "cure." Progress on methadone or buprenorphine tends to look gradual — steadier moods, more consistent sleep, fewer crises — rather than a dramatic before-and-after.
It helps to resist two opposite instincts: pressuring them to get off the medication as fast as possible, and treating the medication itself as the finish line. Both misread what MAT is actually designed to do, which is create enough stability for the psychological and relational work of recovery to happen.
It's also fair to ask your loved one's treatment team how you can be looped in — many programs offer family sessions or education specifically about supporting someone on MAT, since misunderstanding it within a family system is one of the more common reasons people discontinue treatment prematurely.
Frequently Asked Questions
Is medication-assisted treatment just replacing one addiction with another?
No — this is one of the most persistent myths around MAT. Buprenorphine and methadone, when properly dosed and medically supervised, stabilize brain chemistry without producing the euphoria or escalating use pattern that defines addiction. Physical dependence on a stabilizing medication is not the same as active addiction, similarly to how a person can be physically dependent on blood pressure medication without it disrupting their life.
How long does someone typically stay on MAT?
There's no fixed duration. Some people taper off within months; others remain on medication for years or indefinitely. Research consistently shows that longer retention correlates with better long-term outcomes, so families should be cautious about pushing for a fast timeline.
Can someone do MAT without inpatient rehab?
Yes. Many people manage opioid or alcohol use disorder through outpatient MAT combined with counseling, particularly once they're stabilized. Whether inpatient care is needed first often depends on the severity of use, co-occurring mental health conditions, and home environment stability — an assessment can help clarify what level of care makes sense.
Does insurance cover medication-assisted treatment?
Most insurance plans, including Medicaid in all states, are required to cover MAT for opioid use disorder under mental health parity laws, though coverage details, prior authorization requirements, and in-network prescriber availability vary widely by plan and state.
What happens if my loved one relapses while on MAT?
A relapse doesn't mean the medication failed or that treatment should stop — it's typically treated as clinical information that the dose, counseling intensity, or overall plan needs adjustment. Good programs respond to relapse with reassessment, not discharge or punishment.
A Final Word
MAT isn't a shortcut and it isn't a cure — it's a well-evidenced tool that buys time and stability for the harder, slower work of rebuilding a life. Families who go in expecting a straight line from medication to "fixed" often end up disappointed by a process that, in reality, looks more like gradual footing regained after a long fall. The data is clear about survival. What happens after survival is still, largely, up to the work that follows.
RA
Written by
Rehab-Atlas Editorial Team
Our editorial team consists of clinical specialists, addiction counselors, and healthcare writers dedicated to providing accurate, evidence-based information.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment decisions.
Looking for opioid treatment that fits?
Centers vary widely on MAT, detox, and aftercare. The assessment surfaces ones that match.
